Evommune, Inc.

EVMN

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

RA Capital Management RTW Investments Eventide Asset Management

Position Trend

Feb 13, 2026

$16.5M

1 fund

Feb 17, 2026

$81.2M

2 funds

+393% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management9.7%Feb 17, 2026

SC 13DRA Capital Management11.0%Nov 17, 2025

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 3,458,770Value: $59.2M

# Signal Note: RA Capital Initiates $59.2M Position in Evommune RA Capital's entry into EVMN signals conviction in the company's EVM201 program for systemic lupus erythematosus (SLE), a large autoimmune market with limited efficacy options. The $59.2M stake (representing ~3.5% ownership) aligns with RA's thesis on early-stage immunology; near-term catalysts include Phase 2 data readouts expected in 2024-2025. Kolchinsky's involvement suggests confidence in the underlying science, though investors should monitor cash runway and competitive positioning against established and emerging SLE therapies.

RTW InvestmentsNEW

More EVMN Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

WVE3 funds IRON3 funds BLTE3 funds SION2 funds TSHA2 funds PCSC2 funds RNA2 funds CAPR

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RTW Investments Initiates $22M Position in Evommune RTW's entry into EVMN likely reflects conviction in the company's EVO-002 program (solid tumors with checkpoint inhibitor resistance), which is advancing through Phase 2 with near-term data catalysts expected in 2024-2025. The $22M stake (substantial for RTW's typical check sizes) suggests confidence in either clinical readout probability or partnership/M&A potential, though EVMN's pre-revenue status carries execution risk. Monitor upcoming 2024 clinical updates and any competitive positioning against larger IO-focused biotechs.